The Catalyst

Most Recent Posts

07.22.14 | By Stephanie Fischer

In May, the U.S. House Energy and Commerce Committee launched the 21st Century Cures initiative to speed the discovery, development, and delivery of new treatments and cures for patients.  The Committee is conducting a series of hearings and has released white papers on a range of topics to solicit input from patients, researchers, and leaders in government and industry.


Our president and CEO John Castellani asked, “What would happen if the pace of medical innovation in the U.S. slowed or halted altogether?” It’s a scary thought when you consider that without research and development (R&D), the treatments patients have come to depend on and hope to see in the future would not and will not exist.

07.17.14 | By Allyson Funk

Without access to essential health care treatments and services, having health insurance coverage is pointless. Being covered should equate to high-quality, affordable health care, but this is not the case for many individuals in the Affordable Care Act (ACA) health insurance exchanges.

07.17.14 | By Robert Zirkelbach

Vox’s Sarah Kliff talked to some health economists about the new cure for hepatitis C that has gotten so much attention in recent weeks.  What she heard may surprise you.  Check out her article here: Each of these Hepatitis C pills cost $1,000. That's actually a great deal.

Here are a few highlights:


When doctors first began reporting HIV/AIDS cases in the early 1980s there were few effective options that could help combat or manage the deadly disease. As a result, the condition was quickly dubbed a near-certain death sentence.

07.16.14 | By Jeff Francer

Continuing an important conversation about how to make the best use of the wealth of information regarding today’s healthcare treatment options, last week Nicole Fisher wrote in Forbes about the growing need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about medicines.

07.16.14 | By Allyson Funk

The 340B program was created to help vulnerable and uninsured patients access needed medicines. However, the program continues to grow exponentially without appropriate guardrails, putting it at risk. Appropriate oversight and reform is needed to ensure the 340B program can fulfill its promise to patients.

07.15.14 | By Preet Bilinski

Around 2.4 million American adults have schizophrenia each year and onset can be caused by a combination of genetic predisposition and external stressors. Learn more about the 119 medicines in development for mental health.

07.15.14 | By John Castellani

What would happen if the pace of medical innovation in the U.S. slowed or halted altogether? Imagine the treatments and cures that will never come, for Alzheimer’s, for Parkinson’s, for cancers of all kinds.  Imagine also the economic impact: on productivity, on medical costs for people who have conditions without good treatments, on a biopharmaceutical industry that accounts for nearly one out of every five dollars spent on R&D by U.S.

07.15.14 | By Allyson Funk

Patients, especially those suffering from chronic conditions, deserve access to the medicines they need to live longer, healthier lives. The Affordable Care Act’s health insurance exchanges and the Essential Health Benefits they’re meant to provide were supposed to ensure patients have access to the treatments they need. But for many, high out-of-pocket costs create a sometimes insurmountable barrier to access.

07.15.14 | By Brooke Ringel

This week, the European Commission hosts the sixth negotiating round of the Transatlantic Trade and Investment Partnership (TTIP) in Brussels.  As the Commission notes on its website, the discussions will focus on major issue areas including “trade in goods and services, regulatory issues, government procurement, environmental protection and labor rights, energy and raw materials, and opportunities for small- and medium-sized enterprises (SMEs).”  This round, as in the pa

07.14.14 | By Robert Zirkelbach

“Over the next 20 years, total annual medical costs for patients with HCV infection are expected to more than double, from $30 billion to over $85 billion.”


For biopharmaceutical companies, patients are our priority. Throughout the research and development process, it is our job to make sure that innovative, new treatments are moving through the pipeline, into the hands of those in need. To achieve this, a number of different issues must be addressed across the U.S. and around the world. This week, the Catalyst touched on a variety of topics that aren’t typically top-of-mind, but represent just a small sample of issues that are important to helping patients live longer, healthier lives.

07.11.14 | By Randy Burkholder

The debate over the cost and value of innovative medicines has prompted some to make renewed calls for use of a cost-effectiveness or similar standard in the U.S. One example of this was highlighted in a recent column by Ed Silverman at the Wall Street Journal.


Today, Mark Chenoweth of Washington Legal Foundation published a great blog in Forbes (and a similar LTE in San Francisco Chronicle) about upcoming oral arguments for our litigation in Alameda County regarding safe disposal.